Company / Working Capital
CRESCENT BIOPHARMA, INC. Working Capital History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$200.6M
FY2025
5-year range
$34.2M / $200.6M
FY2021-FY2025
Trend
+68.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $34M to $201M over the past 9 years.
Based on SEC 10-K filings.
$201M in FY2025 with a 10-year CAGR of +17.6%.
Improved from $34M to $201M over the past 9 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- +17.6%
Key checks
Key Insights
- In FY2025, working capital increased 68.5% year-over-year.
- Lowest working capital in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.35 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $200.6M | +68.5% |
| FY2017 | $119.0M | +248.2% |
| FY2016 | $34.2M | -13.4% |
| FY2015 | $39.5M | -20.5% |
| FY2014 | $49.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026